type 2 diabetes
Conditions
Interventions
Case series:Nil
Sponsors
Nanjing Drum Tower Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 200 Years
Inclusion criteria
Inclusion criteria: For an eligible patient must meet all of inclusion criteria items: 1. Signed informed consent Form (ICF) obtained before any study-related activities. Studyrelated activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study; 2. Male or female, aged >18 years at the time of signing the ICF; 3. Diagnosed with T2D; 4. Treated with any OAD(s) or basal insulin +/-OAD(s), +/-prandial insulin for at least 20 weeks prior to treatment initiation with Tresiba; 5. The decision to initiate treatment with commercially available Tresiba has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study; 6. Treated with Tresiba (+/- OADs, ±prandial insulin) for at least 20 weeks and have at least one documented medical visit with HbA1c measurement in the first 20 weeks (+/-8 weeks) after Tresiba initiation. The patient may or may not be treated with Tresiba at the time of patient selection to this study; 7. Minimum available data: age, weight, and sex at the time of Tresiba initiation, HbA1c (most recent value within 12 weeks prior to Tresiba? initiation and a value in the first 20 weeks [+/-8 weeks] after Tresiba? treatment), and duration and type of insulin treatment (for insulin treated patients). Note: If the patients have one variable with a missing value in minimum available data set, they will not be included.
Exclusion criteria
Exclusion criteria: 1. Previous participation in this study. Participation is defined as having signed the ICF; 2. Participation (defined as randomisation) in a diabetes clinical trial of an approved or nonapproved investigational medicinal product within 20 weeks prior to the treatment initiation with Tresiba? or during the first 28 weeks of treatment with Tresiba; 3. Tresiba not be used in accordance with the local label; 4. Patients treated with continuous subcutaneous insulin infusion or premix insulin in the 20 weeks prior to receiving Tresiba (short-term [<=14 days] treatment with continuous subcutaneous insulin infusion or premix insulin in the 20 weeks prior to receiving Tresiba? is allowed); 5. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c; | — |
Countries
China
Contacts
Public ContactXia Jiang
Tianjin First Central Hospital
Outcome results
None listed